SCHEDULE: Coastlands Capital Discloses 9.99% Stake in X4 Pharma

Coastlands Capital and its affiliates have reported a 9.99% beneficial ownership stake in X4 Pharmaceuticals, Inc., primarily through pre-funded warrants.

Summary

• Coastlands Capital LP and its affiliated entities (Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry) collectively beneficially own 2,491,638 shares of X4 Pharmaceuticals, Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• The calculation is based on 22,449,689 shares outstanding as of August 13, 2025, and includes 2,491,638 shares issuable upon the exercise of pre-funded warrants held by the reporting persons.
• The 9.99% ownership reflects a beneficial ownership limitation.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• All reporting persons share voting and dispositive power over the 2,491,638 shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by an institutional investor like Coastlands Capital, even if passive, generally indicates a positive view on the company's long-term prospects. The investment through pre-funded warrants suggests a strategic entry point.

Positives

• A significant institutional investor, Coastlands Capital, has taken a substantial 9.99% stake, indicating confidence in X4 Pharmaceuticals.
• The investment is primarily through pre-funded warrants, which can provide capital to the company upon exercise.

Risks

• The beneficial ownership is capped at 9.99% due to a limitation, which might restrict the investor's ability to increase their stake beyond this threshold without further disclosures or potential regulatory implications.

Future Outlook

The filing does not provide any forward-looking statements or guidance from X4 Pharmaceuticals, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

The disclosure of a significant stake by an investment firm like Coastlands Capital in a biotechnology company such as X4 Pharmaceuticals can signal investor interest in the company's pipeline or market position. Such investments are common in the biotech sector, where firms often seek to capitalize on potential drug development successes.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a substantial stake may instill confidence and potentially attract further investor interest.
• Company Management: A large, passive institutional investor can provide a stable shareholder base, though without active control intent.

Key Dates

Recommendation

The filing indicates a significant, passive investment by Coastlands Capital, which is generally a positive signal of institutional confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The investment through pre-funded warrants suggests a prior capital event. Investors should 'hold' and await further operational updates or financial results from X4 Pharmaceuticals to make a more informed decision, while acknowledging the positive signal from this institutional stake.

Keywords

X4 Pharmaceuticals, Coastlands Capital, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, Institutional Investor, Biotechnology, Pharmaceuticals